Cell Line Services GemPharmatech

Cell Line Services GemPharmatech

To support preclinical in-vivo research and development, GemPharmatech has developed a comprehensive platform for gene-edited cell line customization, reporter gene cell line

To support preclinical in-vivo research and development, GemPharmatech has developed a comprehensive platform for gene-edited cell line customization, reporter gene cell line customization, in-vivo mouse tumorigenicity test customization, and cell line-derived xenograft model (CDX model) customization.


GemPharmatech has applied its years of CRISPR-Cas9 experience and expertise from generating genetically engineered mouse models to engineering mouse and human cell lines, in particular syngeneic and patient-derived human tumor cells.

Building on top of an extensive collection of 27 syngeneic cell lines, several of the most popular colorectal, breast, melanoma and liver cancer cell lines have been engineered to express human target genes, including popular IO targets such as PDL1, CD47, CD73, CD39, Nectin4, B7H3, ROR1, CD24A, CD39 and more, providing a growing resource for immune checkpoint drug efficacy evaluation as the filed grows and evolves. 21 of such humanized murine cell lines are available for efficacy services provided by GemPharmatech.

To enable in-vivo non-invasive imaging of tumor growth, GemPharmatech has generated 30 luciferase-tagged murine and human cell lines, comprising solid and hematological malignancies. This provides a valuable tool set for evaluating efficacy of new therapies, treating not only solid tumors, but also liquid and metastatic tumors. These cell lines are also available for efficacy services provided by GemPharmatech.

With these successful applications of engineered cell lines in preclinical studies, GemPharmatech offers cell line engineering services to its clients. Ship your wildtype cell lines and we will return custom-engineered cell lines to you.

Types Times
Humanized mouse tumor cell line customization (One target)+ In-vivo mouse tumorigenicity test 3-4 months+ 2 months
Humanized mouse tumor cell line customization (Multiple targets)+ In-vivo mouse tumorigenicity test Inquire+ 2 months
Gene knockout cell line customization+ In-vivo mouse tumorigenicity test 2-3 months+ 2 months
Transgene overexpression cell line customization (Including reporter genes such as Luciferase) + In-vivo mouse tumorigenicity test 2-3 months+ 2 months

Syngeneic Cell Lines

GemPharmatech has an extensive collection of syngeneic cell lines, including murine-derived cells and genetic modification of the corresponding cells, as well as several popular target cells, including PDL1, CD47, CD73, CD19, CD20, CD33, EGFR, HER2, BCMA, etc., providing a rich resource of tumor models for immune checkpoint drug efficacy evaluation.

Cancer Type Cell Line Background Engineered Human or Mouse Target Availability
Colorectal CT26 BALB/c hPDL1(Tg)-mPDL1(KO) Available
Colorectal CT26 BALB/c hCD47 (Tg)-mCD47(KO) Available
Colorectal CT26 BALB/c hPDL1(Tg)-mPDL1(KO)-hCD47(Tg)-mCD47(KO) Available
Colorectal CT26 BALB/c hPDL1(Tg)-mPDL1(KO)-hCD73(Tg)-mCD73(KO) Available
Colorectal CT26 BALB/c hPDL1(Tg)-mPDL1(KO)-hCD39(Tg)-mCD39(KO) Available
Colorectal CT26 BALB/c hNectin4 (Tg)-mNectin4(KO) Available
Colorectal CT26 BALB/c hPDL1(Tg)-mPDL1(KO)-hB7H3(Tg)-mB7H3(KO) Available
Colorectal CT26 BALB/c hROR1(Tg)-mROR1(KO) Available
Colorectal CT26 BALB/c hPDL1(Tg)-mPDL1(KO)-hCD24A(CD24)(Tg)-mCD24A(CD24)(KO) Available  (Cell only)
Colorectal CT26 BALB/c hCD47(Tg)-mCD47(KO)-hCD24A(CD24)(Tg)-mCD24A(CD24)(KO) Available  (Cell only)
Colorectal MC38 C57BL/6 hPDL1(Tg)-mPDL1(KO) Available
Colorectal MC38 C57BL/6 hCD47 (Tg)-mCD47(KO) Available
Colorectal MC38 C57BL/6 hPDL1(Tg)-mPDL1(KO)-hCD73(Tg)-mCD73(KO) Available
Colorectal MC38 C57BL/6 hPDL1(Tg)-mPDL1(KO)-hB7H3(Tg)-mB7H3(KO) Available
Colorectal MC38 C57BL/6 hPDL1(Tg)-mPDL1(KO)-hCD24A(CD24)(Tg)-mCD24A(CD24)(KO) Available  (Cell only)
Colorectal MC38 C57BL/6 hCD47(Tg)-mCD47(KO)-hCD24A(CD24)(Tg)-mCD24A(CD24)(KO) Available  (Cell only)
Breast EMT6 BALB/c hPDL1(Tg)-mPDL1(KO) Available
Breast EMT6 BALB/c hCD39(Tg)-mCD39(KO) Available
Melanoma B16F10 C57BL/6 hPDL1(Tg)-mPDL1(KO) Available
Liver H22 BALB/c hPDL1(Tg)-mPDL1(KO)-hCD47(Tg)-mCD47(KO) Available
Liver H22 BALB/c hPDL1(Tg)-mPDL1(KO)
Colorectal CT26 BALB/c None Available
Liver H22 BALB/c None Available
Breast 4T1 BALB/c None Available
Breast EMT6 BALB/c None Available
Lymphoma A20 BALB/c None Available
Lymphoma MPC-11 BALB/c None Available
Lymphoma J558 BALB/c None Available
B lymphocyte BcL1 clone 5B1b BALB/c None Available
Renal RENCA BALB/c None Available
Leukemia WEHI-3 BALB/c None Available
Embryonal Carcinoma NFPE BALB/c None Available
Colorectal MC38 C57BL/6 None Available
Lung LLC1 C57BL/6 None Available
Pancreas PAN02 C57BL/6 None Available
Melanoma B16F0 C57BL/6 None Available
Melanoma B16F1 C57BL/6 None Available
Melanoma B16F10 C57BL/6 None Available
Liver Hepa1-6 C57BL/6 None Available
Breast MMT 060562 C57BL/6 None Available
Breast E0771 C57BL/6 None Available
Lymphoma YAC-1 C57BL/6 None Available
Lymphoma E.G7-OVA C57BL/6 None Available
Lymphoblast C1498 C57BL/6 None Available
B lymphocyte HOPC 1F/12 C57BL/6 None Available
Prostate RM-1 C57BL/6 None Available
Sarcoma SaI/N TBD None Available
Bladder MB49 TBD None Available

Reporter Gene Cell Lines

GemPharmatech has several Luciferase-modified cell lines, comprising solid and hematological malignancies, which provide a wealth of tumor models for evaluating efficacy of new cancer therapies. What’s special about these lines? Cell lines that are modified to be tagged with Luciferase allows imaging. That means, as cancer cells metastases/develop across the body, it can be imaged because the luciferase-tag makes it glow under a special machine.

Types Times
Humanized tumor cell line customization (One target) + in-vivo mouse tumorigenicity test 3-4 months + 2 months
Gene knockout cell line customization + in-vivo mouse tumorigenicity test 2-3 months + 2 months
Transgene overexpression cell line customization (Including Reporter gene cell linescustomization) + in-vivo mouse tumorigenicity test 2-3 months + 2 months
Cancer Type Cell Line Availability
Leukemia Nalm6-Luc Available
THP-1-Luc 2023 Q1
K562-Luc Available (Cell only)
Jurkat-Luc 2023 Q1
Liver Cancer Huh7-Luc Available
H22-Luc Available
HepG2-Luc Available (Cell only)
Colorectal Cancer HT-29-Luc Available
HCT116-Luc Available
Colon Cancer RKO-Luc Available
CT26-Luc Available (Cell only)
MC38-Luc Available (Cell only)
Glioblastoma U251-Luc Available
U87-Luc Available
Lymphoma Raji-Luc Available
jeko-1-Luc 2023 Q1
2PK-3-Luc 2023 Q1
U937-Luc Available
A20-Luc Available
MOLM13-Luc Available (Cell only)
Lung Cancer LLC1-Luc Available
A549-Luc Available
Multiple Myeloma RPMI8226-Luc Available
Mouse Pancreatic Cancer KPC-Luc Available
Bladder Cancer MB49-Luc Available
Skin Cancer A375-Luc Available
Ovarian Cancer SKOV3-Luc Available (Cell only)
Breast Cancer 4T1-Luc Available (Cell only)
MDA-MB-231-Luc Available (Cell only)
MDA-MB-468-Luc Available (Cell only)

CDX Cell Lines

Cell line-derived xenograft models (CDX models) are in vivo models where human-derived tumor cells are transplanted into the subcutis of mice for efficacy evaluation or tumor-related research; It is one of the most frequently used in vivo models for preclinical analyses of anticancer medicines.

GemPharmatech’s extensive selection of CDX cell lines, including pancreatic cancer, breast cancer, colon cancer, lung cancer, and lymphoma, can accommodate the requirements of various pharmacodynamic and efficacy investigations. On top of this wide selection, GemPharmatech has engineered 32 CDX cell lines with luciferase to enable non-invasive tumor volume analysis using bioluminescence.

Cancer Type Unmodified Cell Line Luciferase-Tagged Cell Line
Ademocarcimoma Calu-3, NCI-H1666, NCI-H441,NCI-H1650
Acute Myeloid Leukemia MOLM13, OCIAML3
Anaplastic Carcinoma Calu-6
Barett Adenocarcinoma OE33
Bladder Cancer UM-UC-3, HT1376, RT4, T24, RT112/84
Brain Cancer U251, U-87 MG
Breast Cancer BT-20, BT-474, BT-549, HCC1937, HCC1954, HCC1569, Hs 578T, JIMT-1, MCF7, MDA-MB-175VII, MDA-MB-231, MDA-MB-436, MDA-MB-453, MDA-MB-468, SK-BR-3, HCC70, T47D MDA-MB-468-Luc, MDA-MB-231-Luc, MCF-Luc
Chondrosarcoma SW1353
Clear Cell Carcinoma Es-2
Colorectal Cancer Colo205, HCT-116, HT29, HT-55,  LoVo, LS174T, RKO, SW48
Colorectal Cancer; Dukes’ Type C Ls1034
Colorectal Cancer; Dukes’ Type C, Grade III SW948
Colorectal Cancer; Dukes’ Type B SW480
Colon Cancer HT-29-Luc, HCT116-Luc, RKO-Luc
Colon Adenocarcinoma COLO-320
Duodenal Cancer HuTu 80
Endometrial Carcinoma HEC-1-A
Esophagus KYSE-150
Gastric Cancer Hs 746T, MKN45, NCI-N87, SGC-7901, SNU-16, KATOIII, NUGC4
Glioblastoma U251-Luc, U87 MG-Luc
Leukemia HL-60, Jurkat, K562, MOLT-4, MV-4-11, Nalm-6, SUP-B15, THP-1, CCRF-CEM, Hut78, TF1, Hs 505.T Nalm6-Luc, K562-Luc, MOLM 13-Luc, HL60-Luc, MV-4-11-Luc, Jurkat-Luc
Liver Cancer HepG2, Huh7 Huh7-Luc, HepG2-Luc
Lung Cancer A549-Luc, NCI-H82, NCI-H2171
Lymphoma U937, NK92, Jeko-1, Daudi, Ramos, JVM-2, KAPPAS 299, Raj, SU-DHL-10, SU-DHL-16, U-2932, L-540 Raji-Luc, U-937-Luc, MM.1S-Luc, Jeko-Luc, Thp-1-Luc, Daudi-Luc, Ramos
Melanoma A375, COLO829, SK-MEL-28, SK-MEL-5 A375-Luc
Multiple Myeloma NCI-H929, MM.1R, MOLP-8, RPMI-8226,  MM.1S RPMI8226-Luc
Neuroblastoma IMR-32, SK-N-BE(2)
NSCLC A549, HCC-827, NCI-H1703, NCI-H1755, NCI-H1975, NCI-H2122, NCI-H358, NCI-H460, NCI-H1299, NCI-H647
Osteosarcoma MG63
Ovarian Cancer OVCAR-3, SK-OV-3, TOV-112D SKOV3-Luc, OVCAR-Luc
Pancreatic Cancer AsPC-1, BxPC-3, CAPAN-1, CFPAC-1, HPAC, MIA PaCa-2, PANC-1, SW1990 PANC-Luc
Plasmacytoma U-266
Prostate Cancer 22RV1, LNCaP, PC-3, LNCaP C4-2B
Pulmonary Mucoepidermoid Carcinoma NCI-H226, NCI-H292, NCI-H727, NCI-H69
Renal Carcinoma ACHN, 786-O
Sarcoma HT1080, SJSA-1, U-2 OS
SCLC DMS-53, NCI-2171, NCI-H446, NCI-H526, NCI-H82, SHP-77
Skin Cancer A431
Submandibular Adenosquamous Carcinoma A253
Squamous Cell Carcinoma FaDu
Teratocarcinoma PA-1
Tongue Squamous Cell Carcinoma Cal 27
Uterine Cancer HEC-1-A-Luc

For more information, please contact us [email protected]

Want To Inquire About The Services?

Contact Us

THE ATLANTIS BIOSCIENCE DIFFERENCE Discover Translational Solutions To Advance From Bench to Bed

GET SUPPORT Whenever You Need It


Connect With Our Technical Specialist.


Request For A Quotaiton